A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol

A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol

Abstract Background Moderate/severe cases of COVID-19 present a dysregulated immune system with T cell lymphopenia and a hyper-inflammatory state. This is a study protocol of an open-label, multi-center, double-arm, randomized, dose-finding phase I/II clinical trial to evaluate the safety, tolerabil...

Full description

Bibliographic Details
Main Authors: I. García-García, P. Guerra-García, C. Ferreras, A. M. Borobia, A. J. Carcas, J. Queiruga-Parada, J. L. Vicario, I. Mirones, C. Solano, C. Eguizabal, B. Soria, A. Pérez-Martínez
Format: Article
Language:English
Published: BMC 2021-10-01
Series:Trials
Subjects:
COVID-19
Protocol
Allogeneic
Memory T cells
NK cells
Lymphopenia
Online Access:https://doi.org/10.1186/s13063-021-05625-7

Internet

https://doi.org/10.1186/s13063-021-05625-7

Similar Items